{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:17:37Z","timestamp":1786997857100,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1016\/j.ucl.2006.06.006","type":"journal-article","created":{"date-parts":[[2007,1,10]],"date-time":"2007-01-10T09:28:46Z","timestamp":1168421326000},"page":"465-473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Trospium Chloride: Distinct Among Other Anticholinergic Agents Available for the Treatment of Overactive Bladder"],"prefix":"10.1016","volume":"33","author":[{"given":"David R.","family":"Staskin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ucl.2006.06.006_bib1","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1600-0773.1999.tb02026.x","article-title":"Inhibitory effects of trospium chloride on cytochrome P450 enzymes in human liver microsomes","volume":"85","author":"Beckmann-Knopp","year":"1999","journal-title":"Pharmacol Toxicol"},{"key":"10.1016\/j.ucl.2006.06.006_bib2","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2165\/00003088-200544070-00003","article-title":"Clinical pharmacokinetics of trospium chloride","volume":"44","author":"Doroshyenko","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ucl.2006.06.006_bib3","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s003450100225","article-title":"Trospium chloride\u2014an effective drug in the treatment of overactive bladder and detrusor hyperreflexia","volume":"19","author":"H\u00f6fner","year":"2001","journal-title":"World J Urol"},{"key":"10.1016\/j.ucl.2006.06.006_bib4","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1097\/01.ju.0000127742.73136.0c","article-title":"Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial","volume":"171","author":"Zinner","year":"2004","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.ucl.2006.06.006_bib5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.urology.2005.08.017","article-title":"Multicenter phase III trial studying trospium chloride in patients with overactive bladder","volume":"67","author":"Rudy","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2006.06.006_bib6","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1046\/j.1464-410X.2003.04351.x","article-title":"Urodynamic verification of an overactive bladder is not a prerequisite for antimuscarinic treatment response","volume":"92","author":"Malone-Lee","year":"2003","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2006.06.006_bib7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","article-title":"The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society","volume":"61","author":"Abrams","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2006.06.006_bib8","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/01.ju.0000165461.38088.7b","article-title":"A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials","volume":"174","author":"Nixon","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2006.06.006_bib9","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1524-4733.2004.74008.x","article-title":"The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey","volume":"7","author":"Coyne","year":"2004","journal-title":"Value Health"},{"key":"10.1016\/j.ucl.2006.06.006_bib10","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1097\/01.ju.0000154692.73129.d8","article-title":"The Overactive Bladder\u2013Symptom Composite Score: a composite symptom score of toilet voids, urgency severity and urge urinary incontinence in patients with overactive bladder","volume":"173","author":"Zinner","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2006.06.006_bib11","unstructured":"Sand P, Dmochowski R. Trospium chloride improves the symptoms of overactive bladder within one week. Presented at the International Continence Society Meeting. Florence, Italy, 2003. Abstract #370."},{"issue":"3","key":"10.1016\/j.ucl.2006.06.006_bib12","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1464-410X.2006.06035.x","article-title":"Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment","volume":"97","author":"Rudy","year":"2006","journal-title":"BJU Int"},{"issue":"Suppl 1","key":"10.1016\/j.ucl.2006.06.006_bib13","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1097\/01.spv.0000178949.81913.40","article-title":"Trospium chloride demonstrates rapid onset of effect for multiple overactive bladder symptoms in female patients","volume":"11","author":"Garely","year":"2005","journal-title":"J Pelvic Med Surg"},{"key":"10.1016\/j.ucl.2006.06.006_bib14","unstructured":"Odyssey Pharmaceutical Inc. and Indevus Pharmaceuticals Inc. Sanctura\u2122 prescribing information. July 2004. Available at: www.sanctura.com. Accessed April 1, 2006."},{"key":"10.1016\/j.ucl.2006.06.006_bib15","first-page":"423","article-title":"Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder","volume":"5","author":"Staskin","year":"2004","journal-title":"Curr Sci"},{"key":"10.1016\/j.ucl.2006.06.006_bib16","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1464-410X.2005.05296.x","article-title":"Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged \u2265 50 years","volume":"95","author":"Diefenbach","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2006.06.006_bib17","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/BF00191165","article-title":"Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers","volume":"47","author":"Pietzko","year":"1994","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ucl.2006.06.006_bib18","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/00912700122010528","article-title":"Effects of tolterodine, trospium chloride and oxybutynin on the central nervous system","volume":"41","author":"Todorova","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ucl.2006.06.006_bib19","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s11934-003-0023-1","article-title":"Trospium chloride: a quaternary amine with unique pharmacologic properties","volume":"4","author":"Pak","year":"2003","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.ucl.2006.06.006_bib20","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.clinthera.2005.02.014","article-title":"Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly","volume":"27","author":"Scheife","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.ucl.2006.06.006_bib21","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1046\/j.1365-2125.2003.01967.x","article-title":"Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability","volume":"56","author":"Kerbusch","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ucl.2006.06.006_bib22","unstructured":"Astellas Pharma US Inc. and GlaxoSmithKline. VESIcare\u00ae prescribing information. November 2004. Available at: www.vesicare.com\/assets\/vesicare_prescribing_info.pdf. Accessed April 1, 2006."},{"key":"10.1016\/j.ucl.2006.06.006_bib23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1532-5415.1990.tb01593.x","article-title":"Reducing polypharmacy in the elderly. A controlled trial of physician feedback","volume":"38","author":"Kroenke","year":"1990","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.ucl.2006.06.006_bib24","first-page":"85","article-title":"Polypharmacy and the elderly","volume":"Aug","author":"Brazeau","year":"2001","journal-title":"Can J CME"},{"key":"10.1016\/j.ucl.2006.06.006_bib25","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0009-9236(98)90104-7","article-title":"Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine","volume":"63","author":"Brynne","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ucl.2006.06.006_bib26","doi-asserted-by":"crossref","first-page":"223","DOI":"10.5414\/CPP38223","article-title":"Trospium chloride: an effective option for medical treatment of bladder overactivity","volume":"38","author":"Fusgen","year":"2000","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.ucl.2006.06.006_bib27","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1464-410X.2005.05913.x","article-title":"Intravesical instillation of human urine after oral administration of trospium, tolterodine and oxybutynin in a rat model of detrusor overactivity","volume":"97","author":"Kim","year":"2006","journal-title":"BJU Int"},{"issue":"7","key":"10.1016\/j.ucl.2006.06.006_bib28","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1177\/0091270006289481","article-title":"Predictive power of an in vitro system to assess drug interactions of an antimuscarinic medication: a comparison of in vitro and in vivo drug-drug interaction studies of trospium chloride with digoxin","volume":"46","author":"Sandage","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ucl.2006.06.006_bib29","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0022-3565(25)09628-4","article-title":"Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins","volume":"273","author":"Wang","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ucl.2006.06.006_bib30","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0024-3205(98)00581-5","article-title":"Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder","volume":"64","author":"Hegde","year":"1999","journal-title":"Life Sci"},{"key":"10.1016\/j.ucl.2006.06.006_bib31","first-page":"A445","article-title":"Darifenacin is selective for the human recombinant M3 receptor subtype","volume":"21","author":"Napier","year":"2002","journal-title":"Neurourol Urodyn"},{"issue":"Suppl 1","key":"10.1016\/j.ucl.2006.06.006_bib32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1569-9056(02)00045-3","article-title":"Potential benefits of muscarinic M3 receptor selectivity","author":"Andersson","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2006.06.006_bib33","doi-asserted-by":"crossref","first-page":"R874","DOI":"10.1152\/ajpregu.00391.2003","article-title":"The M2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction","volume":"286","author":"Pontari","year":"2004","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.ucl.2006.06.006_bib34","unstructured":"Ortho-McNeil Pharmaceutical, Inc. Ditropan XL prescribing information. June 2003. Available at: www.orthomcneil.com\/products\/pi\/pdfs\/ditropanxl.pdf. Accessed April 1, 2006."},{"key":"10.1016\/j.ucl.2006.06.006_bib35","unstructured":"Pharmacia and Upjohn Company. Detrol\u00ae LA prescribing information. April 2004. Available at: www.detrolla.com\/files\/DetrolLA.pdf. Accessed April 1, 2006."},{"key":"10.1016\/j.ucl.2006.06.006_bib36","unstructured":"Novartis Pharmaceuticals Inc. Enablex\u00ae prescribing information. December 2004. Available at: http:\/\/www.enablex.com\/content\/prescribing.jsp. Accessed April 1, 2006."}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014306000656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014306000656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:18:26Z","timestamp":1758806306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014306000656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["S0094014306000656"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2006.06.006","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trospium Chloride: Distinct Among Other Anticholinergic Agents Available for the Treatment of Overactive Bladder","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2006.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}